Soleno Therapeutics Inc. (SLNO) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Soleno Therapeutics Inc.

    NASDAQ: SLNO · Real-Time Price · USD
    64.96
    2.24 (3.57%)
    At close: Sep 26, 2025, 3:59 PM
    64.76
    -0.31%
    After-hours: Sep 26, 2025, 04:54 PM EDT

    Soleno Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a 1.96M 2.21M 2.21M
    Gross Profit
    		 n/a -1.96M -2.21M -2.21M
    Operating Income
    		 -184.43M -41.38M -24.4M -31.53M
    Interest Income
    		 n/a 2.58M 300K 110K
    Pretax Income
    		 -175.85M -38.99M -24.07M -30.91M
    Net Income
    		 -175.85M -38.99M -20.32M -29.56M
    Selling & General & Admin
    		 105.86M 13.48M 9.84M 10.81M
    Research & Development
    		 78.57M 25.19M 15.27M 21.45M
    Other Expenses
    		 n/a 2.71M n/a n/a
    Operating Expenses
    		 187.67M 41.38M 25.11M 32.26M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 n/a 41.38M 25.11M 32.26M
    Income Tax Expense
    		 n/a n/a -3.75M -1.35M
    Shares Outstanding (Basic)
    		 40.18M 16.49M 8.4M 5.32M
    Shares Outstanding (Diluted)
    		 40.18M 16.49M 8.4M 5.32M
    EPS (Basic)
    		 -4.38 -2.36 -2.42 -5.56
    EPS (Diluted)
    		 -4.38 -2.36 -2.42 -5.56
    EBITDA
    		 -173.63M -37.03M -21.86M -28.7M
    EBIT
    		 -175.62M -38.99M -24.07M -32.26M
    Depreciation & Amortization
    		 n/a 1.96M 2.21M 2.21M

    Add to Watchlist